Press release

Press Release

Cision PR Newswire1 week ago
0

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare’s position across digital health, pharmacy networks, and XRP-based payment infrastructure DUBAI, UAE, Dec. 22,…
Read More »
Press Release

Cision PR Newswire1 week ago
0

Beko Secures €100 Million Sustainability-Linked Loan from IFC to Drive Global Innovation and Net-Zero Transformation

Beko has secured its first sustainability-linked loan to expand renewable energy capacity, strengthen earthquake resilience, and promote next-generation eco-efficient appliances…
Read More »
Business Wire1 week ago

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER,…
Read More »
Business Wire1 week ago

KKR Launches European Rail Leasing Platform with Green Mobility Partners

Strategic partnership to scale newly established locomotive and train leasing company into a leading European rail leasing platform FRANKFURT, Germany–(BUSINESS…
Read More »
Business Wire1 week ago

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER,…
Read More »
Business Wire1 week ago

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

TOKYO–(BUSINESS WIRE)–$INCY–Incyte Biosciences Japan G.K. today announced approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab)…
Read More »
Business Wire1 week ago

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

TOKYO–(BUSINESS WIRE)–$INCY–Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab)…
Read More »
Business Wire1 week ago

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating ENHERTU® (trastuzumab…
Read More »
Business Wire1 week ago

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published

ROME–(BUSINESS WIRE)–Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the…
Read More »
Business Wire1 week ago

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

Tenth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast05 phase 3 trial results…
Read More »

Previous page Next page